| abstract |
The invention relates to KATP channel closers (KCCs) which can be used for the therapeutic and/or prophylactic treatment of an acute injury to the central nervous system (CNS) of a mammal, including a human, given that the administration thereof potentiates the neuroprotective microglial effect, particularly in the case of glibenclamide. As a result, the aforementioned KATP channel closers can be used in the treatment of the acute phase of CNS diseases, such as ictus, convulsions, axonal lesions, traumatic injuries, neurodegeneration, spinal cord lesions and autoimmune and infectious diseases of the CNS. In addition, isotopically-modified KCCs can also be used for the preparation of diagnostic agents for the detection and monitoring of an acute injury to the CNS. |